Pegaspargase

證據等級: L5

預測適應症: 10 個

Pegaspargase: From Acute Lymphoblastic Leukemia to Precursor Lymphoblastic Lymphoma/Leukemia

One-Sentence Summary

Pegaspargase is a PEGylated form of E. coli L-asparaginase used as a cornerstone agent in the treatment of acute lymphoblastic leukemia (ALL). The TxGNN model's top prediction, precursor lymphoblastic lymphoma/leukemia, sits within the same disease spectrum the drug already treats — this is not a novel repurposing hypothesis but a confirmation of established standard-of-care, backed by 50 clinical trials and 20 publications in the evidence pack.

⚠️ Important caveat: Unlike a typical repurposing candidate, this predicted indication overlaps substantially with pegaspargase's known/approved use. The evidence pack's own rationale explicitly flags this as "an extension of an already-established treatment, not a novel repurposing hypothesis." The report below is presented for completeness and regulatory-status tracking, not as a discovery signal.

Quick Overview

Item	Content
Original Indication	Acute lymphoblastic leukemia (ALL) — pegaspargase's established indication, per mechanistic/rationale data in the evidence pack (no Norway license record exists, as the drug is not locally marketed)
Predicted New Indication	Precursor Lymphoblastic Lymphoma/Leukemia
TxGNN Prediction Score	99.96%
Evidence Level	L1
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Pegaspargase depletes serum asparagine by hydrolyzing it into aspartic acid and ammonia. Lymphoblasts characteristically lack (or have very low) asparagine synthetase, meaning they cannot synthesize their own asparagine and depend entirely on the extracellular pool — depletion by pegaspargase is therefore selectively lethal to these cells while sparing most normal tissues, which retain synthetase activity. This is a well-established, decades-old mechanism, not a newly inferred one.

"Precursor lymphoblastic lymphoma/leukemia" and "acute lymphoblastic leukemia" describe overlapping points on the same disease continuum (WHO classification treats ALL and lymphoblastic lymphoma as the same neoplasm presenting either in blood/marrow or as a nodal/extranodal mass). Because pegaspargase's antineoplastic mechanism targets the shared metabolic vulnerability of lymphoblasts regardless of presentation (leukemic vs. lymphomatous), the TxGNN prediction is mechanistically sound — but it largely reflects confirmation of existing practice rather than a new therapeutic hypothesis.

Detailed formal MOA documentation (DrugBank original_moa field) was not available in this evidence pack; the mechanistic description above is derived from the model's own repurposing rationale rather than a structured DrugBank entry, and should be independently verified before use in regulatory submissions.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02013167	Phase 3	Terminated	405	Blinatumomab vs. standard-of-care chemotherapy (pegaspargase-containing backbone) in relapsed/refractory B-precursor ALL (TOWER study)
NCT00103285	Phase 3	Completed	5,377	Large randomized comparison of combination chemotherapy regimens in newly diagnosed standard-risk B-precursor ALL
NCT00022737	Phase 3	Completed	220	COG pilot study of combination chemotherapy ± donor stem cell transplant in very high-risk pediatric ALL
NCT03643276	Phase 3	Recruiting	5,000	AIEOP-BFM ALL 2017 international collaborative protocol for children/adolescents with ALL
NCT00005945	Phase 3	Completed	3,054	Escalating-dose IV methotrexate vs. oral methotrexate and intensification strategies in standard-risk pediatric ALL
NCT03959085	Phase 3	Recruiting	5,951	Inotuzumab ozogamicin added to post-induction chemo-immunotherapy for high-risk B-ALL
NCT02881086	Phase 3	Completed	1,023	Pediatric-inspired, MRD-directed therapy incl. nelarabine consolidation in adult ALL/lymphoblastic lymphoma
NCT05602194	Phase 3	Recruiting	440	Levocarnitine prophylaxis against asparaginase-associated hepatotoxicity in AYA ALL/LL patients
NCT06195735	N/A	Completed	649	Forecasting hypersensitivity to PEG-asparaginase to optimize ALL treatment outcomes
NCT00671034	Phase 3	Completed	166	Calaspargase pegol vs. pegaspargase pilot RCT in newly diagnosed high-risk ALL

40 additional trials were identified in the evidence pack but are omitted here for brevity (full list available in the raw Evidence Pack).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37276451	2023	Cohort	Blood Advances	GIMEMA LAL1913: pegaspargase-modified, risk-oriented program improves outcomes in adult Ph-negative ALL/LL
34228505	2021	Cohort	J Clin Oncol	DFCI 11-001: efficacy/toxicity comparison of pegaspargase vs. calaspargase pegol in childhood ALL
35271306	2022	Phase 3 RCT	J Clin Oncol	COG AALL1231: bortezomib added to therapy in newly diagnosed T-ALL/T-LL
39322712	2024	Phase 2	Leukemia	Long-term follow-up: venetoclax + hyper-CVAD/nelarabine/pegylated asparaginase in T-ALL/LBL
40109190	2025	Review	Haematologica	Expert panel consensus on recognition/prevention/management of asparaginase-related adverse events in adults
27114587	2016	Phase 3 RCT	J Clin Oncol	COG AALL0232: dexamethasone + high-dose methotrexate improve outcomes in high-risk B-ALL
32813610	2020	Phase 3 RCT	J Clin Oncol	COG AALL0434: nelarabine tested in newly diagnosed T-cell ALL
17696798	2007	Review	Expert Opin Pharmacother	Foundational review of PEG-asparaginase pharmacology and clinical role
40163215	2025	Phase 2	Int J Hematol	Multicenter study of lyophilized pegaspargase efficacy/safety/PK in Japanese ALL patients
35987855	2022	Review	Bulletin du Cancer	French Society of Children/Adolescent Cancers recommendations on managing pegaspargase-associated toxicities

10 additional publications were identified in the evidence pack but are omitted here for brevity.

Norway Market Information

No authorizations are currently registered for pegaspargase in Norway (market status: Not Marketed, total licenses: 0). If clinical use is pursued, access would require a named-patient/exemption import route or a new marketing authorization application, rather than reliance on an existing local license.

Cytotoxicity

Pegaspargase is an antineoplastic biologic enzyme (L-asparaginase class) used exclusively in cytotoxic chemotherapy regimens for lymphoid malignancies; its original indication (ALL) and mechanism (selective cytotoxicity via asparagine depletion) both meet the criteria for this section.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — enzyme-based antimetabolic agent (asparaginase class), distinct in mechanism from DNA-damaging cytotoxics
Myelosuppression Risk	Not directly characterized in the available evidence; pegaspargase is generally considered less myelosuppressive on its own than classic cytotoxics, but it is invariably administered within multi-agent regimens where overall myelosuppression is driven by co-administered drugs (per trial NCT01193933, dosing is modified based on combined regimen myelosuppression severity)
Emetogenicity Classification	Low to moderate (consistent with the asparaginase drug class)
Monitoring Items	Liver function (hepatotoxicity — PMID 34528411, 40109190), pancreatic enzymes/pancreatitis (PMID 10696127), coagulation parameters (thrombosis/hemostasis — NCT01094392), triglycerides and glucose (PMID 30823860, 34931744), and hypersensitivity monitoring (PMID 31571395, NCT06195735)
Handling Protection	Must be handled under standard cytotoxic/antineoplastic drug handling precautions

Safety Considerations

Please refer to the package insert for safety information. No structured key warnings, contraindications, or drug–drug interaction data were available in this evidence pack (DDI query returned no results).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic and clinical trial evidence (L1, 50 trials including large Phase 3 RCTs) is strong, but this is fundamentally confirmatory evidence for pegaspargase's already-established role in ALL/lymphoblastic lymphoma rather than a genuine repurposing discovery. Combined with the drug's current unmarketed status in Norway and a blocking data gap on local product labeling, this candidate should proceed only under guardrails — not as a novel indication launch.

To proceed, the following is needed:

TFDA/Norway-equivalent package insert warnings and contraindications (currently a Blocking data gap — DG001)
Formal DrugBank-sourced mechanism of action documentation (currently a High-severity data gap — DG002)
Confirmation of regulatory pathway for Norway market access (named-patient import vs. new MA application), given zero current authorizations
Clarification with clinical/regulatory stakeholders that this candidate represents confirmation of existing use, not a new repurposing opportunity, before including it in any repurposing-focused decision packet
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.